IL-8 induces imbalances between nitric oxide and endothelin-1, and also between plasminogen activator inhibitor-1 and tissue-type plasminogen activator in cultured endothelial cells
Date
2008Author
Cheng, M
Li, Y
Wu, J
Nie, Y
Li, L
Liu, X
Charoude, HN
Chen, H
Metadata
Show full item recordAbstract
Interleukin-8 (IL-8), a member of the CXC chemokine family, plays an important role in the modulation of multiple biological functions in endothelial cells containing the receptors CXCR1 and CXCR2. It has previously been shown that IL-8 directly enhances endothelial cell survival, and stimulates the production of matrix metalloproteinases, which in turn regulates angiogenesis. However, its role in the regulation of the production of vasoactive substances in endothelial cells is less well defined. In this study, we investigate the effects of IL-8 on the proliferation of human umbilical vein endothelial cells (HUVECs). In addition, we also study the effects of IL-8 on the production of vasodilator, vasoconstrictor and fibrinolytic factors in these cells. The results show that recombinant IL-8 (50-200 ng/ml) induces neither HUVEC proliferation nor nitric oxide (NO) release. However, it significantly increases the production of endothelin-1 (ET-1) in a concentration-dependent manner. Furthermore, incubation of endothelial cells with IL-8 (200 ng/ml) up-regulates the plasminogen activator inhibitor-1 (PAI-1) in HUVECs, while it down-regulates the tissue plasminogen activator (t-PA). These findings suggest that IL-8 offsets the balance between endothelial vasoconstrictors and vasodilators. Furthermore, IL-8 also leads to an imbalance between PAI-1 and t-PA, which causes the ECs to become procoagulative and hypofibrinolytic. آ© 2007 Elsevier Ltd. All rights reserved.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke
Zamanlu, M; Farhoudi, M; Eskandani, M; Mahmoudi, J; Barar, J; Rafi, M; Omidi, Y (2018)Tissue plasminogen activator (tPA) is the only FDA approved medical treatment for the ischaemic stroke. However, it associates with some inevitable limitations, including: short therapeutic window, extremely short half-life ... -
Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
Sadeghi-Hokmabadi, E; Farhoudi, M; Taheraghdam, A; Hashemilar, M; Savadi-Osguei, D; Rikhtegar, R; Mehrvar, K; Sharifipour, E; Youhanaee, P; Mirnour, R (2016)Background: In developing countries, intravenous thrombolysis (IVT) is available at a limited number of centers. This study aimed to assess the feasibility and safety of IVT at Tabriz Imam Reza Hospital. Methods: In a ... -
Safety and Feasibility of Intravenous Tissue Plasminogen Activator (IV-tPA) in Acute Ischemic Stroke Patients, Update on Tabriz Thrombolytic Therapy on Acute Ischemic Stroke (T3AIS) Project
Hokmabadi, ES; Farhoudi, M; Oskouei, DS; Taheraghdam, A; Hashemilar, M; Yazdchi, M; Mehrvar, K; Ghiasi, RR; Hassasi, R; Farzi, MA; Aliyar, H; Mehdizadeh, E; Tamar, SH; Hadavibavili, M (2016)